Insulin pumps and CGM devices can help youth with T1D achieve better glycemic control and alleviate self-care burden. However, not all youth want to use such devices. We compared psychosocial characteristics of teens with T1D and their parents/caregivers according to teen pump use vs. non-use as well as teen CGM use vs. non-use. At baseline, teens/parents completed psychosocial surveys assessing teen depressive symptoms [CESD], disordered eating behaviors, diabetes-specific family conflict, parent involvement in diabetes care, teen self-care, diabetes burden (PAID-Ped/PR), quality of life, and major life events. Diabetes treatment data were collected by interview and EHR review every 3 months for 18 months. Teens using/starting pump or CGM at all/most visits were considered pump users or CGM users, respectively. Chi-square and t-tests compared characteristics of device (pump, CGM) users with non-users. The sample comprised 301 teens aged 13-17 with T1D (41% male); mean age was15.0±1.3 years, T1D duration 6.5±3.7 years, and A1c 8.5±1.1%. Neither age, sex, nor T1D duration was related to device use. CGM and pump non-users had less favorable survey scores than device users for many psychosocial characteristics (Table). Identifying teens with less favorable psychosocial factors may help target those at risk for device non-use, allowing timely intervention and support by clinicians when initiating diabetes technologies.View largeDownload slideView largeDownload slide DisclosureC. Chen: None. L. J. Tinsley: None. L. K. Volkening: None. B. Anderson: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc.FundingNational Institutes of Health (R01DK095273, T32DK007260, P30DK036836); JDRF (2-SRA-2014-253-M-B)